Karen Breen

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacem...